Drug Trial Radar · NCT06489808
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Last checked: Nov 20, 2026Latest source record: Jul 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
89
Planned (sponsor's estimate)
Start
May 28, 2024
Primary completion
Dec 31, 2026
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
Conditions
- Relapsed/Refractory Large B-Cell Lymphoma
Interventions
LinperlisibDrug
Linperlisib RP2D D1-14
RituximabDrug
rituximab 375 mg/m2 D0
GemcitabineDrug
gemcitabine per regimen dosage
OxaliplatinDrug
Oxaliplatin 130 mg/m2 D1
IfosfamideDrug
Ifosfamide 5g/m2 D2
CarboplatinDrug
Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
EtoposideDrug
Etoposide 100mg/m2 D1-3
DexamethasoneDrug
Dexamethasone 40mg D1-4
CisplatinDrug
Cisplatin 100mg/m2 D1, continuous intravenous infusion
Ara-CDrug
Ara-C 2g/m2 q12h D2
VinorelbineDrug
Vinorelbine 20mg/m2 D1
Mitoxantrone hydrochloride liposomeDrug
Mitoxantrone hydrochloride liposome 18mg/m2 D1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting ToxicitiesTime frame: Safety Run-in Period, up to the end of cycle 1 (each cycle is 21 days)
- ORRTime frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Disease Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.